TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Nov. 25, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (
NASDAQ: TLX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Lost Money on Telix Pharmaceuticals Ltd. (TLX)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskySearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Lost Money on Telix Pharmaceuticals Ltd. (TLX)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyNEW YORK - November 24, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. (
NASDAQ: TLX) of a class action securities lawsuit.
Shareholders That Lost Money on Telix Pharmaceuticals Ltd. (TLX) Should Contact Levi & Korsinsky About Pending Class Action - TLXNEW YORK - November 21, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. (
NASDAQ: TLX) of a class action securities lawsuit.
Shareholders That Lost Money on Telix Pharmaceuticals Ltd. (TLX) Should Contact Levi & Korsinsky About Pending Class Action - TLXSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (
NASDAQ: TLX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Bragar Eagel & Squire, P.C. Reminds Investors of Telix, Freeport, and Primo Brands to Contact the Firm About their Rights Before Lead Plaintiff DeadlinesNEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Telix Pharmaceuticals Limited (
NASDAQ:TLX), Freeport-McMoran Inc. (
NYSE:FCX), and Primo Brands Corporation (
NYSE:PRMB). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
TLX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix PharmaceuticalsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options
Investors Who Lost Money on Telix Pharmaceuticals Ltd. (TLX) Should Contact Levi & Korsinsky About Pending Class Action - TLXSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Investors Who Lost Money on Telix Pharmaceuticals Ltd. (TLX) Should Contact Levi & Korsinsky About Pending Class Action - TLXNEW YORK - November 20, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. (
NASDAQ: TLX) of a class action securities lawsuit.
ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal MassesMELBOURNE, Australia and INDIANAPOLIS, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces results from the ZIRCON-X study which finds that almost half of all patients imaged with TLX250-CDx (Zircaix®1, 89Zr-DFO-girentuximab) PET/CT2 would have undergone a change in clinical management, when compared with baseline standard of care (SOC) imaging. The data will be presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO) being held in Phoenix, AZ, December 2 – 5, 2025.
Shareholders of Telix Pharmaceuticals Ltd. Should Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights - TLXSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Shareholders of Telix Pharmaceuticals Ltd. Should Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights - TLXNEW YORK - November 19, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. (
NASDAQ: TLX) of a class action securities lawsuit.
TLX LAWSUIT ALERT: Levi & Korsinsky Notifies Telix Pharmaceuticals Ltd. Investors of a Class Action Lawsuit and Upcoming DeadlineSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
TLX LAWSUIT ALERT: Levi & Korsinsky Notifies Telix Pharmaceuticals Ltd. Investors of a Class Action Lawsuit and Upcoming DeadlineNEW YORK - November 18, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. (
NASDAQ: TLX) of a class action securities lawsuit.
Deadline Alert: Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Glancy Prongay & Murray LLP reminds investors of the upcoming January 9, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Telix Pharmaceuticals Limited (“Telix” or the “Company”) (
NASDAQ: TLX) securities between February 21, 2025 and August 28, 2025, inclusive (the “Class Period”).
TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (
NASDAQ: TLX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Deadline Approaching: Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Urged to Contact Law Offices of Howard G. Smith
Law Offices of Howard G. Smith reminds investors of the upcoming January 9, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Telix Pharmaceuticals Limited (“Telix” or the “Company”) (
NASDAQ: TLX) securities between February 21, 2025 and August 28, 2025, inclusive (the “Class Period”).
Law Offices of Frank R. Cruz Encourages Telix Pharmaceuticals Limited (TLX) Shareholders to Inquire About Securities Fraud Class Action
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased Telix Pharmaceuticals Limited (“Telix” or the “Company”) (
NASDAQ: TLX) securities between February 21, 2025 and August 28, 2025, inclusive (the “Class Period”). Telix investors have until January 9, 2026 to file a lead plaintiff motion.
